“The sale of our concrete products business was a transformational event,” said Lynn Schuler, Cretex’s president and CEO. “This divestiture positions us to aggressively drive growth by expanding both our production capabilities and our engineering services to better serve all of our medical markets.”
The Cretex Medical family of companies’ capabilities include precision machining, plastic injection molding, laser processing, precision stamping, metal fabrication, and clean room assembly and packaging.
“We will be actively looking to acquire additional capabilities to better serve our customers,” said Schuler. “The medical device contract manufacturing industry is undergoing unprecedented change as the large OEMs as well as small startups are looking for reliable, full-service strategic sourcing partners. Our strong balance sheet and long-term focus puts Cretex Medical in a unique position to strengthen our market presence by investing heavily in cutting-edge technologies and capabilities to drive innovation, reduce costs, and increase value for our customer base.”